<DOC>
	<DOCNO>NCT02257398</DOCNO>
	<brief_summary>This Phase I , 4-period , randomize , active-and placebo-controlled , double-blind crossover , single-dose study evaluate effect therapeutic ( 1000 milligram [ mg ] ) supratherapeutic ( 1800 mg ) dose GSK2140944 positive control ( moxifloxacin 400 mg ) placebo correct QT interval ( QTc ) assess continuous 12-lead Holter electrocardiogram ( ECGs ) approximately 55 healthy volunteer . All subject receive single dos GSK2140944 1000 mg , GSK2140944 1800 mg , moxifloxacin 400 mg , placebo randomize sequence . A double-dummy approach use maintain blinding . Thus , dose day , moxifloxacin moxifloxacin placebo GSK2140944 placebo administer . Subjects screen within 30 day prior entry clinic . Subjects report clinical unit Day -2 Period 1 Day -1 subsequent period . Subjects remain confined check procedure complete Day 3 ( 5 day confinement Period 1 4 day follow 3 period ) . There washout least 7 day dos . The follow-up visit occur 7-10 day final dose . Total duration study ( screen follow-up visit ) approximately 60 day .</brief_summary>
	<brief_title>Placebo Moxifloxacin Controlled Cardiac Conduction Study GSK2140944 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female 18 55 year age , inclusive , time signing informed consent Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test , cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include investigator feel document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 kilogram ( kg ) body mass index within range 19 31 kilogram / square meter ( kg/m^2 ) ( inclusive ) . A female subject eligible participate pregnant ( confirm negative serum betahuman chorionic gonadotrophin test ) , lactate , least one follow condition applies : Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation , document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , hysterectomy , document bilateral oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea . To confirm postmenopausal status , blood sample simultaneous folliclestimulating hormone ( FSH ) &gt; 40 milliinternational unit per mililiter ( mlU/mL ) estradiol &lt; 40 picogram/milliliter ( pg/mL ) ( &lt; 147 picomole/liter [ pmol/L ] ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Reproductive potential agrees follow one option list GSK Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) requirement 30 day prior first dose study drug least 7 day last dose study drug completion followup visit . This list apply FRP sex partner , prefer usual lifestyle subject continue abstinent penilevaginal intercourse longterm persistent basis . Contraceptive subdermal implant meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label , intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label , oral contraceptive , either combined progestogen alone , injectable progestogen , contraceptive vaginal ring , percutaneous contraceptive patch , male partner sterilization documentation azoospermia prior female subject 's entry study , male sole partner subject . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent describe protocol , include compliance requirement restriction list consent form protocol Alanine aminotransferase ( ALT ) bilirubin &lt; 1.5 × upper limit normal range ( ULN ) . Isolated bilirubin &gt; 1.5 × ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % . One repeat test confirm result acceptable . Serum potassium , calcium , magnesium laboratory parameter within normal limit screen checkin . History/evidence arrhythmia ( example , second thirddegree heart block , atrial fibrillation , supraventricular tachycardia , symptomatic sinus bradycardia , junctional rhythm ) clinically significant cardiac disease procedure ( mitral valve regurgitation , heart murmur , angina/ischemia , congenital heart abnormality , coronary artery bypass grafting surgery , percutaneous transluminal coronary angioplasty ) . A history additional risk factor torsades de pointes ( e.g. , heart failure , hypokalemia , family history long QT syndrome ) . Current chronic history liver disease know hepatic biliary abnormality ( exception Gilbert syndrome asymptomatic gallstone ) . Any clinically significant CNS ( e.g. , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic , GI condition history condition , opinion investigator , may place subject unacceptable risk participant trial may interfere absorption , distribution , metabolism , excretion drug . History photosensitivity quinolones . Use systemic antibiotic within 30 day screen . Confirmed lifetime history C. difficile diarrhea History spontaneous tendon rupture History smoking use nicotine containing product within 3 month screen positive urine cotinine indicative smoking screening . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 fluid ounce ( fl oz ) ( 360 millilitre [ mL ] ) beer , 5 fl oz ( 150 mL ) wine , 1.5 fl oz ( 45 mL ) 80proof distilled spirit . History sensitivity study drug component thereof history drug allergy , opinion investigator GSK medical monitor , contraindicate potential subject 's participation . History sensitivity heparin heparininduced thrombocytopenia ( clinical research unit use heparin maintain IV cannula patency ) . A positive prestudy hepatitis B surface antigen positive hepatitis C antibody result within 3 month screen positive human immunodeficiency virus ( HIV ) antibody . A positive urine test drug abuse screen Day 1 ; positive urine test alcohol ( alcohol breath test ) within 24 hour dose study . Exclusion criterion screen baseline ECG ( single repeat test allow eligibility determination ) : Heart rate : &lt; 40 &gt; 100 beat per minute ( bpm ) ( For male ) , &lt; 45 &gt; 100 bpm ( For Females ) ; PR interval &lt; 120 &gt; 220 millisecond ( msec ) ; QRS duration &lt; 70 &gt; 110 msec ; QTcF interval &gt; 450 msec . Evidence previous myocardial infarction ( include STsegment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , atrioventricular block [ second degree high ] , WolffParkinsonWhite syndrome ) , sinus pause &gt; 3 second , nonsustained sustain ventricular tachycardia ( &gt; 3 consecutive ventricular ectopic beat ) , significant arrhythmia , opinion investigator GSK medical monitor , interfere safety individual subject . An abnormal finding clinical significance arrhythmia detection Holter perform Day 2 , view investigator would compromise subject safety interfere study procedures assessment exclude study . Full disclosures review detail review maintain part subject 's source document . Analysis Holter recording consider follow : Heart rate ( significant brady tachycardia , base investigator 's judgment ) Reports symptomatic arrhythmia ( except isolate extrasystole ) Normal aberrant beat Number supraventricular contraction , premature atrial contraction , premature ventricular contraction , couplet , triplet , ventricular tachycardia Atrioventricular conduction defect Atrial fibrillation flutter Participation study would result donation blood blood product excess 500 mL within 56day period . Participation clinical trial subject receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives , twice duration biological effect investigational product ( whichever longer ) . Exposure 4 new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>GSK2140944</keyword>
	<keyword>TQTc</keyword>
	<keyword>Moxifloxacin</keyword>
</DOC>